Genfit, once considered among the frontrunners in the biotech race to commercialize a treatment for nonalcoholic steatohepatitis (NASH), has come up short. The French company said Monday that its investigational treatment, elafibranor, did not meet the main goal of a late-stage trial evaluating its ability to resolve the fatty liver disease without worsening related scarring.
That’s according to an analysis of interim data from the RESOLVE-IT study, which looked at results from about 1,000 patients of the roughly 2,000 enrolled in the trial after 72 weeks.
Genfit (NASDAQ: GNFT) CEO Pascal Prigent, speaking on a conference call Monday, said early… Read more »
UNDERWRITERS AND PARTNERS
